strategies to minimize the risk of stent thrombosis, especially in high-risk pa-tients (see Procedural Factors). Procedural Factors Procedural factors associated with stent thrombosis include the stent type selected (whether BMS or DES, and even the specific DES used), as well as whether the stent is adequately ex-panded and apposed to the. How to minimize stent thrombosis. Kirtane AJ(1), Stone GW. Author information: (1)Columbia University Medical Center/New York-Presbyterian Hospital, USA. PMID: 21911796 [Indexed for MEDLINE] Publication Types: Case Reports; Review; MeSH terms. Angioplasty, Balloon, Coronary/adverse effects* Coronary Disease/diagnostic imaging The mechanisms underlying stent thrombosis are multifactorial and include patient-related factors, procedural factors (including stent choice) and post procedural factors (including type and. Stefanini GG, Byrne RA, Serruys PW et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISARTEST 4, and LEADERS randomized trials. Eur. Heart J. 33(10), 1214-1222 (2012) Optimum technique to reduce risk of stent thrombosis - Authors' reply. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. with 3389 randomised patients was underpowered to detect small differences in this low-frequency endpoint, and that the suggestion of.
Patient education is critically important to prevent stent thrombosis. It is mandatory that patients who receive a stent are educated about the importance of dual antiplatelet therapy and the recommended duration of therapy. Any deviation from this recommendation (i.e., for a surgical procedure) should be under the direction of a cardiologist Stent selection and deployment Strategies to Minimize the Occurrence of Stent Thrombosis. Consider use of stents with proven lower stent thrombosis rates Appropriate vessel sizing High-pressure stent deployment and post-dilation Ensuring absence of edge dissection The two major causes of stent failure are stent thrombosis (ST) and in-stent restenosis (ISR). The incidence of both has reduced considerably in recent years. Current clinical registries and randomized trials with broad inclusion criteria show rates of ST at or <1% after 1 year and ∼0.2-0.4% per year thereafter; rates of clinical ISR are 5%. New-Generation DES Reduce Restenosis, Stent Thrombosis PARIS, France—In a real-world population, percutaneous coronary intervention (PCI) with newer-generation drug-eluting stents (DES) significantly reduces the risk of restenosis and stent thrombosis compared with first-generation DES at 2 years Technical improvements, such as the use of adequately sized balloons and high-pressure deployment, helped to substantially decrease thrombosis rates. [ 3, 6] In addition, a regimen of..
How to minimize stent thrombosis. Kirtane AJ 1, Stone GW. Author information. Affiliations. 1 author. 1. Columbia University Medical Center/New York-Presbyterian Hospital, USA. Circulation, 01 Sep 2011, 124(11): 1283-1287 DOI: 10.1161/circulationaha. Thus, mortality due to stent thrombosis has been reported to be as high as 45 % (3). Definition and classification. A new standard definition of stent thrombosis was recently proposed by an Academic Research Consortium (ARC) in order to make it possible to compare the true rates of stent thrombosis across different trials and registries (4) Stent Thrombosis. Stent thrombosis is a rare but devastating complication of PCI. Mortality rates are reported from 25% to 40%. Stent thrombosis is defined as acute (<24 hours), subacute (within 30 days), late (between 1 month and 1 year), or very late (>1 year)
Early stent thrombosis carries a higher risk of cardiac death compared with late or very late events in a broad range of CAD patients, according to a study published online March 24, 2015, ahead of print in the American Journal of Cardiology. While [stent thrombosis] remains infrequent, continued efforts to determine how to reduce [the complication], particularly within the first 30 days. But together with the growing use of stents, stent thrombosis, the most feared complication after stent implantation, has emerged as an important entity to understand and prevent. Adjunct pharmacological therapy, stent design, and deployment technique have been adjusted ever since to reduce its occurrence A person with a stent should be aware of sudden feelings of shortness of breath or angina. There are guidelines for prevention of stent thrombosis. When patients receive a stent, they will usually also take two medications that reduce platelet aggregation and production. Since the 2010s medication guidelines have slightly changed Stent thrombosis (ST) is an uncommon but highly morbid complication of percutaneous coronary interventions. The mechanisms leading to ST are heterogeneous, likely accounting for the variable timing and outcomes of ST. For the clinician, it is important to recognize major risk factors for ST, including discontinuation of dual antiplatelet therapy Stent selection to minimize the risk of stent thrombosis. Palmerini, Tullio a; Biondi-Zoccai, Giuseppe b; Stone, Gregg W. c. Current Opinion in Cardiology: November 2014 - Volume 29 - Issue 6 - p 578-585. doi: 10.1097/HCO.0000000000000102. ISCHEMIC HEART DISEASE: Edited by Peter H. Stone.
The most dreaded complication with percutaneous coronary intervention with stents, either bare-metal or drug-eluting stents is stent thrombosis (ST) and it has a significant detrimental effect on the outcome for the patient. The initial attempts at intervention with bare-metal stents had much higher How to minimize stent thrombosis. Circulation 124, 1283-1287. Kleinschmidt KC (2006). Epidemiology and pato-physiology of acute coronary syndrome. John Hopkins Advanced Studies in Nursing 4, 72-77. Kumar A and Cannon CP (2009). Acute coronary syndromes: diagnosis and management, part I. Mayo Clinic Proceedings 84, 917-938 Blood Clots and Travel: What You Should Know. This podcast is designed to help people reduce their risk of blood clots during long-distance travel of four hours or more. Listen now. More than 300 million people travel on long-distance flights (generally more than four hours) each year. 1 Blood clots, also called deep vein thrombosis (DVT), can.
As a three-component system, newer designs can improve healing and reduce the risk of stent thrombosis by improvement in any of these areas. As noted in Table 1, the EES and ZES have thinner struts, while the EES also has a substantially lower total dose. Both newer devices also have markedly thinner polymers, with other unique polymer. Perioperative stent thrombosis eviewr Percutaneous coronary intervention with stent placement is one of the most frequently performed procedures in the western world. Patients with coronary stents need to be on dual antiplatelet therapy in order to minimize the risk of stent thrombosis. When these patients undergo surgical procedures, th Dual antiplatelet therapy (DAPT) must be continued for the recommended duration to reduce the risk of stent thrombosis and other major adverse cardiac events Complication 3: Stent thrombosis Dinh Duc Huy, MD, FSCAI Interventional Cardiology Tam Duc Cardiology Hospital Heart Institute- Ho Chi Minh City- CME- Interventional - A free PowerPoint PPT presentation (displayed as a Flash slide show) on PowerShow.com - id: 7f8d8f-MGE1 Stent thrombosis is rare but potentially devastating and can result in ST-segment elevation myocardial infarction or death.The aim of this article is to review the incidence, To reduce the risk of thrombosis in drug-eluting stents, it may be important to use thes
Treating Deep Vein Thrombosis with Angioplasty and Stenting. With deep vein thrombosis (DVT), blood clots form in the large veins deep within the legs, pelvis and sometimes in the arms. DVT strikes about 1 in 20 people over the course of a lifetime. Sometimes a blood clot may break free from a deep vein, as in diagram #3 here Coronary artery stents are used in the majority of patients who undergo percutaneous coronary intervention (PCI), as they significantly reduce the need for repeat target vessel revascularization compared to balloon angioplasty. (See Intracoronary stent restenosis, section on 'Incidence of restenosis' .) Stent thrombosis is an uncommon but. Risk factors for stent thrombosis Prior stent thrombosis is an important risk factor for future stent thrombosis as well. Diffuse multivessel disease, especially in the presence of diabetes mellitus, enhances the risk of stent thrombosis. Chronic kidney disease is another risk factor. Certain anatomical features also increase the risk of stent thrombosis like three or [
Adverse events, like late stent thrombosis, are very rare. Angioplasty and stents have been extremely successful in opening clogged arteries and improving the lives of patients. Over six million drug-eluting stents have been implanted and it is only over very widespread use that these rare complications emerge: a variety of studies worldwide. Byrne concluded that despite failing to reduce bleeding and failing to show noninferiority with regard to thrombotic events, the Cobra stent was safe, with stent thrombosis rates considerably lower than those seen in earlier trials with high-bleeding-risk patients, despite only 14 days of DAPT drug-eluting stent (DES): mesh tubes that release medication into your artery to reduce scar tissue formation and prevent narrowing Both DESs and BMSs are meant to be permanent Devise antiplatelet strategies to minimize the risk for stent thrombosis in patients with drug-eluting stents Disclosures As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest Patients who have received a stent receive dual antiplatelet therapy (DAPT) to reduce the risk of stent thrombosis. But DAPT comes with a tradeoff: in a landmark 2014 NEJM study, longer DAPT was associated with lower stent thrombosis and other major cardiac adverse events, but higher bleeding and higher all-cause mortality. Some contemporary observers attributed the mortality finding to chance.
Thrombosis occurs when blood clots block veins or arteries. Symptoms include pain and swelling in one leg, chest pain, or numbness on one side of the body. Complications of thrombosis can be life-threatening, such as a stroke or heart attack. Treatment includes medicines that thin the blood or prevent clots, and using stents or catheters to. We can treat this with angioplasty (widening the vein), or by inserting a mesh-like tube called a stent to keep the vein open. While there is a small risk of bleeding from the procedure, DVT thrombolysis can speed the recovery from DVT and help to minimize future scarring of the veins from DVT Cardiovascular Research Foundation. (2014, March 27). Anti-clotting agent helps reduce incidence, impact of stent thrombosis during PCI. ScienceDaily. Retrieved July 18, 2021 from www.sciencedaily. Stent Thrombosis Redux — The FDA Perspective Dr. Andrew Farb and Ashley Boam write that as compared with on-label use, off-label use of drug-eluting stents is associated with increased risks of.
stent thrombosis and restenosis, requiring re-peat revascularization in many patients.1 The risk of stent thrombosis was found to be miti-gated by aspirin and 1 month of ticlopidine, sparking the initial enthusiasm for DAPT as we know it today.2 Drug-eluting stents were subsequently de-veloped to reduce the risk of stent restenosis. Waksman explained that most of the stent thrombosis in the study occurred in the first 30 days, and that this type of stent thrombosis is more related to mechanical issues, whereas late stent thrombosis, occurring after a year or more, is more tied to healing and inflammation or responsiveness to Plavix Despite the improvement in stent technology, stent thrombosis (ST), a potentially catastrophic event, still occurs. Among several risk factors for ST, high on-treatment platelet reactivity to clopi..
SCAI. To understand late stent thrombosis it is helpful to know exactly what a stent is. A stent is a medical device designed to keep a blocked artery in the heart open, allowing blood to flow freely through the artery. A physician, usually an interventional cardiologist, inserts a stent in the heart either to help prevent a future heart attack. The complication of stent thrombosis (ST) emerged at a rate of 0.5% annually for first-generation drug-eluting stents (DES), often presenting as death or myocardial infarction. Procedural factors such as stent underexpansion and malapposition are risk factors for ST in patients. The type of lesion being treated and lesion morphology also influence healing after treatment with DES and can. The Potential Impact of Deep Vein Thrombosis. A blood clot in one of the large veins, usually in a person's leg or arm, is called a deep vein thrombosis or DVT. When a DVT forms, it can partially or completely block the flow of blood through the vein. If a DVT is not treated, it can move or break off and travel to the lungs On this observation, Dangas noted that optimizing adjunctive pharmacotherapy appears to be particularly important to reduce acute and subacute stent thrombosis with bivalirudin and that more use.
Reduce risk of stent thrombosis Life threatening event which occurs while stent is in process of endothelialization Classification and criteria for stent thrombosis Important note: Does NOT mitigate risk of in-stent restenosis (which is a more chronic process due to endothelial overgrowth and is not influenced by DAPT) Long term goa FDA Issues Complete Response Letter for XARELTO ® (rivaroxaban) to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome. Raritan, NJ (June 28, 2013) - Janssen Research & Development, LLC (Janssen) today announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the supplemental New Drug Application (sNDA) for XARELTO® (rivaroxaban.
Deep venous thrombosis (DVT) affects approximately one in 1,000 patients yearly, and 40-70% of these patients will develop post-thrombotic syndrome (PTS) in their lifetime: a constellation of symptoms and signs of chronic venous insufficiency, including pain, swelling, varicose veins, and ulcerations. 1,2 PTS is associated with profound morbidity and cost, which justifies the attention it. stent thrombosis: A blood clot that forms inside a device inserted into a blood vessel to keep that vessel open. Patient Care Stents are deployed in completely obstructed or partially blocked arteries to keep blood flowing through them to the organs they supply. When this blood flow stops due to clotting within the stent, the organ may become. The importance of adequate anticoagulation to prevent early thrombosis after stenting of stenosed venous bypass grafts Stent implantation in native coronary arteries may be complicated by acute thrombosis, despite the use of stringent anticoagulation A stent is a small mesh tube inserted into an artery to keep it open. A drug-eluting stent is coated with a slow-release medication to help prevent blood clots from forming in a stent. Blood clotting in a stent can cause a future blockage (restenosis) and may lead to a heart attack. Stents without a drug coating are called bare-metal stents Shorter maintenance of dual antiplatelet therapy might minimize the risk for stent thrombosis in cases of discontinuation of antiplatelet regimen and prevent wasteful medications and bleeding complications related with dual antiplatelet therapy. Thus, the EPC capture stent might be valuable for the elderly because they are vulnerable to.
The most important factor influencing acute stent thrombosis appeared to be use of early nonrandomized heparin before patients had been randomized to the study drug. Patients who received such treatment had significantly lower rates of stent thrombosis within the first 24 hours regardless of which treatment group they were assigned to Those at high risk of stent thrombosis (see Table 1) After PCI, the uninterrupted use of warfarin is critical to minimize the risk of valve thrombosis. When patients with mechanical heart valves undergo PCI with or without ACS, triple therapy with OAC, clopidogrel and ASA should be used initially.. eCOBRA is a prospective, consecutively enrolled, observational, multi-center, all-comers study that demonstrated positive outcomes in patients at high risk of bleeding and stent thrombosis in a real-world setting
However, a common complication is stent thrombosis, or a clot forming in the stent, which occurs more quickly in bare metal stents and is often delayed in drug-eluding stents. Patients receiving a stent are recommended to be on dual antiplatelet therapy, or DAPT, consisting of a P2Y 12 inhibitor, such as clopidogrel or ticagrelor, and aspirin Stent thrombosis is an uncommon, but potentially catastrophic complication that may occur after a stent has been inserted into a patient's coronary artery and causes clots to form. If blood flow is significantly restricted or completely blocked, this can result in unstable angina, myocardial infarction or even death, with incident rates as. COBRA REDUCE's final co-primary endpoint analysis at 6 months and secondary endpoints, including composite of all-cause death, cardiac death, MI, ischemia-driven TLR, definite and probable stent thrombosis and ischemic stroke at 12 months are expected to be revealed in early 2021 The use of intravascular ultrasound (IVUS) to improve acute angiographic results was already shown in the prestent era. Various studies demonstrated the efficacy of IVUS in balloon sizing and estimating the extent of positive remodeling. With the introduction of drug-eluting stents (DES) the rate of restenosis has been significantly reduced but a new concern, the risk of stent thrombosis, has. Both stents were postdilated with a 8 × 40 mm Dorado PTA balloon (Bard Peripheral Vascular, Inc., Tempe, AZ) (Figure 2(e)) to minimize in-stent restenosis and stent thrombosis. There was no residual stenosis and the pressure gradient dropped to zero with normal flow noted through the iliac artery and the kidney allograft artery (Figure 2(f) )
Estradiol has been shown to promote rapid reendothelialization of the stent and to reduce the restenosis after PCI. This trial will compare the anti-restenotic efficacy of the polymer-free rapamycin plus 17β estradiolvalerat -eluting stent with that of the polymer-free rapamycin-eluting stent in patients with coronary artery disease Stent thrombosis occurs when blood pools at the site of an implanted stent within a patient's coronary artery. Stent thrombosis is an uncommon, but serious complication that can result in a heart. Nowadays, stent thrombosis (ST) represents a rare but still devastating outcome after percutaneous coronary intervention (PCI) with contemporary stent platforms. The majority of patients present with acute myocardial infarction (AMI), mostly ST-segment elevation myocardial infarction (STEMI), due to thrombotic occlusion of the previously. ation DES have been developed using different platforms, alternative drugs, and either more biocompatible durable polymers or bioabsorbable polymers. In this review, we will analyze whether the improved technology of this new class of devices has improved their safety profile. Recent findings Recent data accruing from frequentist and network meta-analysis have challenged the notion that DES. Drug therapy to reduce stent thrombosis. Dual antiplatelet therapy. The key element in the prevention of stent thrombosis lies in the prescription of dual antiplatelet therapy.
Additional stent implantation is not absolutely necessary and is advised for treatment of significant residual dissections. 10. Finally, an optimal procedural result is important to minimize the risk of ST. Proper stent expansion and apposition over the full length of the stent should be ascertained, and residual dissections should be avoided Though rare, blood clots that occur within a stent (stent thrombosis) can lead to heart attack and stroke. To prevent blood clots from forming, patients may be instructed to take anti-clotting medication for up to a year or more, depending on the type of stent they receive, and they may be instructed to take aspirin for life Drug-Eluting stents reduce risk of thrombosis 23 March 2012 Cobalt-chromium everolimus eluting stents are associated with a significantly lower rate of stent The overall rate of thrombosis over the follow which ranged up to four years was 1.4 per hundred person-years for everolimus eluting stents. The figure was 2.9 for sirolimus eluting stents and 4.4 for paclitaxel eluting stents (p<0.0001). The rates of early and late stent thrombosis were also similarly lower Stent thrombosis, also known as abrupt vessel closure and acute stent thrombosis, is one of the fatal complications of percutaneous coronary intervention. A high clinical suspicion is needed for the evaluation of this condition, and measures are needed to promptly restore patency of the thrombosed vessels
In-stent restenosis (ISR) Angioplasty, a type of percutaneous coronary intervention (PCI), is a procedure used to open up blocked arteries. During the procedure, a small metal scaffold, called a. evidence of low stent thrombosis After receiving a DES, patients need to take blood thinners—to prevent blood clot formation (stent thrombosis) which could potentially lead to a heart attack. One indicator of XIENCE safety is apparent in a meta-analysis, which examined data from 50,844 patients across 49 high-quality randomized controlled trials . The EU-wide consortium improved diagnostic tools and investigated technical measures to prevent or reduce the occurrence of stent thrombosis The finding that CoCr-EES also reduced stent thrombosis compared with bare-metal stents, if confirmed in future randomized trials, represents a paradigm shift, the authors write. Continue Readin
Early stent thrombosis is procedure related. Late stent thrombosis can be caused by delayed healing, malapposition, uncovered struts. Very late stent thrombosis might be caused by an abnormal local vascular response: neoatherosclerosis. Biodegradable vascular scaffolds might face a rate of stent thrombosis as high as 0.9-3% The PTFE-covered stent used for coronary stent grafting still has limitations. It was recently reported by Kawamoto et al. that the use of the PTFE-covered stent is associated with high rates of stent thrombosis throughout the long-term follow-up period (2% at 1 year and 5% at 3 years), even in patients receiving DAPT .Although little information is available regarding the mechanism of stent. stent thrombosis occurring more than one year after stent placement. 15 Late cardiac death and MI occurred in 4.9 percent of patients with drug-eluting stents
.1 2 However, a reduced response to clopidogrel occurs in a signif-icant proportion of patients, leading to worse cardiovascular outcomes.3 In the cerebral circula-tion, in-stent thrombosis can result in devastating stroke or death. We report a case of reduced. Plavix combined with aspirin, called dual anti-platelet therapy or DAPT, reduce the risk of stent thrombosis which can result in myocardial infarction and death. After implantation of a bare metal stent, the risk of stent thrombosis is highest in the 1st few days to weeks after implant. For this reason, the DAPT is recommended for a minimum of. The drug eluting stents consist of a bare-metal stent coated with a drug encapsulated polymer which gradually releases the drug over time. These types of stents can be made in a variety of different ways which opens the opportunity for a vast amount of applications. The type of metal that is used for the mesh can be altered, and more. The American College of Cardiology and a multidisciplinary French Task Force have recently published guidance on perioperative stent thrombosis.1 2 We summarise these guidelines and highlight several simple steps that can be taken to minimise the risk of this potentially life threatening perioperative condition. The introduction of coronary stents revolutionised percutaneous intervention in.
stent thrombosis was requested. Even in a case with aneurysm infection, stent graft repair may be an acceptable method to minimize invasion of concomitant surgical intervention New-generation drug-eluting stents reduce stent thrombosis and myocardial infarction: A propensity-score-adjusted analysis from the multicenter REAL registry (REgistro Regionale AngiopLastiche Dell'Emilia-Romagna) Luigi Vignali, Francesco Saia, Laura Maria Beatrice Belotti, Emilia Solinas, Paolo Guastaroba, Andrea Rubboli, Antonio Manari.
A DVT is a blood clot that forms deep in your veins, most often in your leg. It can partially or completely block blood flow back to the heart and damage the one-way valves in your veins. It can. Deep vein thrombosis (DVT, also called venous thrombosis) is a blood clot that develops in a vein deep in the body. The clot may partially or completely block blood flow through the vein. Most DVTs occur in the lower leg, thigh or pelvis, although they also can occur in other parts of the body including the arm, brain, intestines, liver or kidney An endovascular covered-stent has unique advantages in treating complex intracranial aneurysms; however, in-stent stenosis and late thrombosis have become the main factors affecting the efficacy of covered-stent treatment. Smooth-muscle-cell phenotypic modulation plays an important role in late in-stent stenosis and thrombosis. Here, we determined the efficacy of using covered stents loaded. Drug-eluting stents (DESs) can effectively control the harmful effects of coronary artery disease, because of their excellent ability to reduce in-stent restenosis. However, delayed re-endothelialization and late stent thrombosis have caused concern over the safety of DESs. In this study, according to time-
Accessed June 18, 2011. analyzed only late (⬎1 month) stent thrombosis, a 40% relative risk reduction in the rate of stent thrombosis, although not statistically significant, was found in patients allocated to biode- Reply gradable polymer stents (0.27% vs. 0.45%, respectively; odds ratio: 0.68; 95% confidence interval: 0.32 to 1.48; p ⫽ 0.33) stent thrombosis are also similar within the early and late time intervals and across stent types and include various patient, lesion, and procedural characteristics.25-27 The most important of these factors for early or late stent thrombosis are stent length, residual dissection, diabetes, stent underex • Stent thrombosis is a clinically important event, causing often death or myocardial infarction in those experiencing it • Stent thrombosis is however rare, it is crucial to individualize management strategies in order to maximize benefits and minimize risks 34 Thank you for your attention. It is recommended that you take Brilinta for at least 12 months after having a stent placement to reduce the risk of stent thrombosis. If therapy is stopped early a stent thrombosis could develop resulting in a heart attack. Recent studies suggest that taking anti-platelets for longer (up to 30 months) may reduce your risk even further but may. of in-stent thrombosis. A retrospective observational trial has suggested that triple antiplatelet therapy using aspirin, clopidogrel and cilostazol may further reduce the risk of stent thrombosis especially in patients or lesions at increased risk with no difference in the rate of major bleeding . The advent of prasugrel as
Early stent era data suggested that this level of stent deployment, as evidenced by intravascular ultrasound (IVUS) examination, would reduce acute stent thrombosis. 10 However, the advent of powerful anti-platelet therapy, such as combined Aspirin and Clopidogrel, and glycoprotein 2b3a inhibitors, made acute stent thrombosis much less of an. Table 1 Types of stent thrombosis which were reported Studies Type of stent thrombosis reported Follow-up period Type of participants Type of stent Ahn2008  Acute, sub-acute and late ST 6 months PCI in patients with T2DM DES Gao2013  Definite, probable, acute and late ST 1 year PCI in patients with obesity DE Generally, a stent should only be placed after flow has been restored in a vessel which has AVC. In this case, following pre-dilatation of a calcified lesion there was AVC of the LM due to acute thrombosis/Type F dissection. Intracoronary vasodilators were given with no improvement in flow
. 24 /PRNewswire/ -- In order to further advance understanding of stent thrombosis, Cordis announced today a study of the multiple factors that may lead to the condition and. the risk of stent thrombosis fully explained to everyone concerned. The case also lends support to the AHA guideline that aspirin should be continued if at all possible and the thienopyridine restarted as soon as possible after the procedure to minimize the concerns about late-stent thrombosis . Our experience support the presumption tha Thrombosis that was considered definite or probable, a more specific assessment of the rates of thrombosis in the two treatment arms according to the ARC definitions, was 1.6 percent (13 out of 832 patients) in the CYPHER® Stent group and 1.7 percent (15 out of 870 patients) in the bare-stent arm from zero-four years
. Coronary stents are implanted in more than 1.5 million patients each year. Stent thrombosis is an uncommon, but catastrophic complication that may occur after a stent has been inserted into a patient's coronary artery BACKGROUND. The Kounis syndrome was first reported in 1991 as an acute coronary syndrome, including coronary spasm (type I), atheromatous plaque erosion or rupture (type II) and stent thrombosis (ST) (type III), resulting from allergic or hypersensitivity reactions, or anaphylactic or anaphylactoid insults.1 In type III, all three components of drug-eluting stents (stent metals, polymers and.